However, there was a decline in speech and upper limb function, manifesting with bradylalia, bradykinesia, and dysphonia, which decreased after treatment with trihexyphenidyl.<h4>Conclusion</h4>Although reports of patients with monogenic dystonia, particularly DYT-<i>THAP1</i>, treated with DBS are still scarce, DBS should be considered as an efficient treatment approach in children with pharmacoresistent dystonia, especially with generalized monogenic dystonia and to prevent severe and disabling symptoms that reduce the quality of life, including emotional and social aspects. The gene discussed is THAP1; the disease is Dystonia.